Your browser doesn't support javascript.
loading
The validity of progression-free survival 2 as a surrogate trial end point for overall survival.
Woodford, Rachel G; Zhou, Deborah D-X; Kok, Peey-Sei; Lord, Sally J; Friedlander, Michael; Marschner, Ian C; Simes, R John; Lee, Chee Khoon.
Afiliación
  • Woodford RG; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
  • Zhou DD; St George Cancer Care Centre, Sydney, New South Wales, Australia.
  • Kok PS; Chris O'Brien Lifehouse, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Lord SJ; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
  • Friedlander M; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
  • Marschner IC; Nelune Cancer Centre, Prince of Wales Hospital and Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
  • Simes RJ; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
  • Lee CK; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
Cancer ; 128(7): 1449-1457, 2022 04 01.
Article en En | MEDLINE | ID: mdl-34985773

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Año: 2022 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Año: 2022 Tipo del documento: Article País de afiliación: Australia